Strides Pharma Science Ltd
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
- Market Cap ₹ 5,607 Cr.
- Current Price ₹ 608
- High / Low ₹ 786 / 322
- Stock P/E 22.5
- Book Value ₹ 246
- Dividend Yield 0.41 %
- ROCE 7.85 %
- ROE 4.48 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Promoter holding is low: 26.8%
- Company has a low return on equity of -4.67% over last 3 years.
- Promoters have pledged 54.2% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Total Market BSE Allcap Nifty Microcap 250 BSE Healthcare BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2012 | Mar 2014 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
962 | 1,341 | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 4,051 | 4,492 | |
861 | 1,567 | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,351 | 2,779 | 3,201 | 3,544 | 3,484 | 3,712 | |
Operating Profit | 101 | -226 | 229 | 374 | 527 | 398 | 197 | 401 | 537 | -131 | 145 | 568 | 781 |
OPM % | 10% | -17% | 19% | 13% | 19% | 14% | 9% | 15% | 16% | -4% | 4% | 14% | 17% |
959 | 3,281 | 874 | 63 | 291 | 643 | 303 | -30 | 109 | -112 | 92 | -95 | 16 | |
Interest | 79 | 109 | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 314 | 287 |
Depreciation | 31 | 56 | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 221 | 195 |
Profit before tax | 949 | 2,890 | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -63 | 315 |
Tax % | 11% | 39% | 15% | 31% | 12% | 1% | -9% | 27% | 11% | -27% | -21% | 50% | |
847 | 1,767 | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 241 | |
EPS in Rs | 143.92 | 296.43 | 141.78 | 12.15 | 44.71 | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 26.97 |
Dividend Payout % | 1% | 170% | 76% | 41% | 10% | 3% | 8% | 345% | 8% | 0% | -7% | -33% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 13% |
3 Years: | 7% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | -25% |
5 Years: | -20% |
3 Years: | -23% |
TTM: | 2306% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 27% |
3 Years: | 58% |
1 Year: | 61% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 0% |
3 Years: | -5% |
Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 59 | 60 | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 |
Reserves | 1,967 | 947 | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,179 |
1,594 | 547 | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 2,308 | |
1,175 | 543 | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,410 | |
Total Liabilities | 4,796 | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,990 |
3,017 | 555 | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,987 | |
CWIP | 241 | 99 | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 154 |
Investments | 0 | 443 | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 243 |
1,538 | 999 | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,605 | |
Total Assets | 4,796 | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,990 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
139 | -272 | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | |
771 | 4,044 | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | |
-990 | -3,319 | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | |
Net Cash Flow | -80 | 454 | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 183 | 99 | 119 | 132 | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 103 |
Inventory Days | 328 | 90 | 135 | 149 | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 251 |
Days Payable | 344 | 137 | 153 | 188 | 221 | 188 | 299 | 259 | 311 | 260 | 220 | 189 |
Cash Conversion Cycle | 168 | 52 | 102 | 92 | 120 | 71 | 160 | 119 | 140 | 168 | 165 | 164 |
Working Capital Days | 18 | 53 | -29 | 96 | 63 | 117 | 155 | 95 | 116 | 210 | 156 | 141 |
ROCE % | 27% | 113% | 57% | 8% | 11% | 16% | 6% | 5% | 8% | -5% | -0% | 8% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 19 Feb
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Feb - About newspaper advertisement regarding dispatch of Postal Ballot Notice dated January 30, 2025.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 17 Feb
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4 Feb - Transcript of Q3 earnings call for Strides Pharma.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 Jan - Newspaper publication of unaudited financial results for the quarter and nine months ended December 31, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2025Transcript PPT REC
-
Oct 2024TranscriptPPT
-
Oct 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]